NCT02328443View on ClinicalTrials.gov

Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

Midazolam

DRUG

itraconazole

DRUG

rifampicin

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02328443 - Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI | Biotech Hunter | Biotech Hunter